Literature DB >> 21326550

Liver regeneration and the atrophy-hypertrophy complex.

Robin D Kim1, Jae Sung Kim, Go Watanabe, Dagmara Mohuczy, Kevin E Behrns.   

Abstract

The atrophy-hypertrophy complex (AHC) refers to the controlled restoration of liver parenchyma following hepatocyte loss. Different types of injury (e.g., toxins, ischemia/reperfusion, biliary obstruction, and resection) elicit the same hypertrophic response in the remnant liver. The AHC involves complex anatomical, histological, cellular, and molecular processes. The signals responsible for these processes are both intrinsic and extrinsic to the liver and involve both physical and molecular events. In patients in whom resection of large liver malignancies would result in an inadequate functional liver remnant, preoperative portal vein embolization may increase the remnant liver sufficiently to permit aggressive resections. Through continued basic science research, the cellular mechanisms of the AHC may be maximized to permit curative resections in patients with potentially prohibitive liver function.

Entities:  

Keywords:  Portal vein embolization; atrophy-hypertrophy complex; liver regeneration

Year:  2008        PMID: 21326550      PMCID: PMC3036484          DOI: 10.1055/s-2008-1076679

Source DB:  PubMed          Journal:  Semin Intervent Radiol        ISSN: 0739-9529            Impact factor:   1.513


  120 in total

1.  Oriental cholangiohepatitis: correlation between portal vein occlusion and hepatic atrophy.

Authors:  S Kusano; Y Okada; T Endo; H Yokoyama; H Ohmiya; H Atari
Journal:  AJR Am J Roentgenol       Date:  1992-05       Impact factor: 3.959

2.  Application of preoperative portal vein embolization before major hepatic resection in patients with normal or abnormal liver parenchyma.

Authors:  Hisao Wakabayashi; Ken Ishimura; Keiichi Okano; Yukihiko Karasawa; Fuminori Goda; Takashi Maeba; Hajime Maeta
Journal:  Surgery       Date:  2002-01       Impact factor: 3.982

3.  Calpain mediates ischemic injury of the liver through modulation of apoptosis and necrosis.

Authors:  V Kohli; J F Madden; R C Bentley; P A Clavien
Journal:  Gastroenterology       Date:  1999-01       Impact factor: 22.682

4.  Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor.

Authors:  Y Yamada; I Kirillova; J J Peschon; N Fausto
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

5.  Apoptosis of sinusoidal endothelial cells occurs during liver preservation injury by a caspase-dependent mechanism.

Authors:  S Natori; M Selzner; K L Valentino; L C Fritz; A Srinivasan; P A Clavien; G J Gores
Journal:  Transplantation       Date:  1999-07-15       Impact factor: 4.939

6.  The compensatory hyperplasia (liver regeneration) following ligation of a portal branch is initiated before the atrophy of the deprived lobes.

Authors:  L Lambotte; B Li; I Leclercq; C Sempoux; A Saliez; Y Horsmans
Journal:  J Hepatol       Date:  2000-06       Impact factor: 25.083

7.  Nonoperative approach to hilar cancer determined by the atrophy-hypertrophy complex.

Authors:  N S Hadjis; A Adam; R Gibson; J I Blenkharn; I S Benjamin; L H Blumgart
Journal:  Am J Surg       Date:  1989-04       Impact factor: 2.565

8.  The mitochondrial permeability transition augments Fas-induced apoptosis in mouse hepatocytes.

Authors:  E Hatano; C A Bradham; A Stark; Y Iimuro; J J Lemasters; D A Brenner
Journal:  J Biol Chem       Date:  2000-04-21       Impact factor: 5.157

9.  Role of liver atrophy, hepatic resection and hepatocyte hyperplasia in the development of portal hypertension in biliary disease.

Authors:  N S Hadjis; L H Blumgart
Journal:  Gut       Date:  1987-08       Impact factor: 23.059

10.  Nitric oxide is released in regenerating liver after partial hepatectomy.

Authors:  S Hortelano; B Dewez; A M Genaro; M J Díaz-Guerra; L Boscá
Journal:  Hepatology       Date:  1995-03       Impact factor: 17.425

View more
  18 in total

Review 1.  Local Arterial Therapies in the Management of Unresectable Hepatocellular Carcinoma.

Authors:  Samdeep K Mouli; Laura W Goff
Journal:  Curr Treat Options Oncol       Date:  2017-10-27

2.  Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update.

Authors:  Shiv Kumar Sarin; Ashok Choudhury; Manoj K Sharma; Rakhi Maiwall; Mamun Al Mahtab; Salimur Rahman; Sanjiv Saigal; Neeraj Saraf; A S Soin; Harshad Devarbhavi; Dong Joon Kim; R K Dhiman; Ajay Duseja; Sunil Taneja; C E Eapen; Ashish Goel; Q Ning; Tao Chen; Ke Ma; Z Duan; Chen Yu; Sombat Treeprasertsuk; S S Hamid; Amna S Butt; Wasim Jafri; Akash Shukla; Vivek Saraswat; Soek Siam Tan; Ajit Sood; Vandana Midha; Omesh Goyal; Hasmik Ghazinyan; Anil Arora; Jinhua Hu; Manoj Sahu; P N Rao; Guan H Lee; Seng G Lim; Laurentius A Lesmana; Cosmas Rinaldi Lesmana; Samir Shah; V G Mohan Prasad; Diana A Payawal; Zaigham Abbas; A Kadir Dokmeci; Jose D Sollano; Gian Carpio; Ananta Shresta; G K Lau; Md Fazal Karim; Gamal Shiha; Rino Gani; Kemal Fariz Kalista; Man-Fung Yuen; Seema Alam; Rajeev Khanna; Vikrant Sood; Bikrant Bihari Lal; Viniyendra Pamecha; Ankur Jindal; V Rajan; Vinod Arora; Osamu Yokosuka; Madunil A Niriella; Hai Li; Xiaolong Qi; Atsushi Tanaka; Satoshi Mochida; Dominic Ray Chaudhuri; Ed Gane; Khin Maung Win; Wei Ting Chen; Mohd Rela; Dharmesh Kapoor; Amit Rastogi; Pratibha Kale; Archana Rastogi; Chhagan Bihari Sharma; Meenu Bajpai; Virender Singh; Madhumita Premkumar; Sudhir Maharashi; A Olithselvan; Cyriac Abby Philips; Anshu Srivastava; Surender K Yachha; Zeeshan Ahmad Wani; B R Thapa; Anoop Saraya; Ashish Kumar; Manav Wadhawan; Subash Gupta; Kaushal Madan; Puja Sakhuja; Vivek Vij; Barjesh C Sharma; Hitendra Garg; Vishal Garg; Chetan Kalal; Lovkesh Anand; Tanmay Vyas; Rajan P Mathur; Guresh Kumar; Priyanka Jain; Samba Siva Rao Pasupuleti; Yogesh K Chawla; Abhijit Chowdhury; Shahinul Alam; Do Seon Song; Jin Mo Yang; Eileen L Yoon
Journal:  Hepatol Int       Date:  2019-06-06       Impact factor: 6.047

3.  Partial liver volume radioembolization induces hypertrophy in the spared hemiliver and no major signs of portal hypertension.

Authors:  Nerea Fernández-Ros; Nuno Silva; Jose Ignacio Bilbao; Mercedes Iñarrairaegui; Alberto Benito; Delia D'Avola; Macarena Rodriguez; Fernando Rotellar; Fernando Pardo; Bruno Sangro
Journal:  HPB (Oxford)       Date:  2013-03-27       Impact factor: 3.647

4.  Aberrant gastric venous drainage and associated atrophy of hepatic segment II: computed tomography analysis of 2021 patients.

Authors:  Tae Won Choi; Jin Wook Chung; Hyo-Cheol Kim; Jin Woo Choi; Myungsu Lee; Saebeom Hur; Hwan Jun Jae
Journal:  Abdom Radiol (NY)       Date:  2020-09

Review 5.  Liver-directed therapies in metastatic colorectal cancer.

Authors:  Margaret E Clark; Richard R Smith
Journal:  J Gastrointest Oncol       Date:  2014-10

Review 6.  Portal vein embolization for hepatocellular carcinoma.

Authors:  Junichi Shindoh; Ching-Wei D Tzeng; Jean-Nicolas Vauthey
Journal:  Liver Cancer       Date:  2012-11       Impact factor: 11.740

7.  Implementing Radiation Dose-Volume Liver Response in Biomechanical Deformable Image Registration.

Authors:  Daniel F Polan; Mary Feng; Theodore S Lawrence; Randall K Ten Haken; Kristy K Brock
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-06-27       Impact factor: 7.038

Review 8.  Strategies to increase the resectability of hepatocellular carcinoma.

Authors:  Wong Hoi She; Kenneth Sh Chok
Journal:  World J Hepatol       Date:  2015-08-28

Review 9.  Interventional treatment for unresectable hepatocellular carcinoma.

Authors:  Satoru Murata; Takahiko Mine; Fumie Sugihara; Daisuke Yasui; Hidenori Yamaguchi; Tatsuo Ueda; Shiro Onozawa; Shin-ichiro Kumita
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

10.  Compensatory hypertrophy of the liver after external beam radiotherapy for primary liver cancer.

Authors:  Chai Hong Rim; Sangjoon Park; Joong Yeol Woo; Jinsil Seong
Journal:  Strahlenther Onkol       Date:  2018-08-13       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.